Abs Biotechnologies

Developer of human cell-based platform for cardiovascular drug safety assessment

placeTulln, Lower Austria, Austria calendar_todayFounded 2022 language absbiotechnologies.com

Social engagement

Social engagement: 1.9K social following, 7 posts in the last 12 months — below the industry typical range.

Investor mix

1 investor on record.

Investor typeCountShare
Accelerator & incubator1100%

Recent activity

1 Jul 2026
Event
International Society for Stem Cell Research 2026 Annual Meeting
29 May 2026
Product launch
Pasaxial Mesoderm Smooth Muscle Cells (PM-SMCs)
14 Apr 2026
Event
Babraham Research Campus
Coming soon